• Medientyp: E-Artikel
  • Titel: USP22 regulates APL differentiation via PML-RARα stabilization and IFN repression
  • Beteiligte: Kowald, Lisa; Roedig, Jens; Karlowitz, Rebekka; Wagner, Kristina; Smith, Sonja; Juretschke, Thomas; Beli, Petra; Müller, Stefan; van Wijk, Sjoerd J. L.
  • Erschienen: Springer Science and Business Media LLC, 2024
  • Erschienen in: Cell Death Discovery
  • Sprache: Englisch
  • DOI: 10.1038/s41420-024-01894-8
  • ISSN: 2058-7716
  • Schlagwörter: Cancer Research ; Cell Biology ; Cellular and Molecular Neuroscience ; Immunology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>Ubiquitin-specific peptidase 22 (USP22) is a deubiquitinating enzyme (DUB) that underlies tumorigenicity, proliferation, cell death and differentiation through deubiquitination of histone and non-histone targets. Ubiquitination determines stability, localization and functions of cell fate proteins and controls cell-protective signaling pathways to surveil cell cycle progression. In a variety of carcinomas, lymphomas and leukemias, ubiquitination regulates the tumor-suppressive functions of the promyelocytic leukemia protein (PML), but PML-specific DUBs, DUB-controlled PML ubiquitin sites and the functional consequences of PML (de)ubiquitination remain unclear. Here, we identify USP22 as regulator of PML and the oncogenic acute promyelocytic leukemia (APL) fusion PML-RARα protein stability and identify a destabilizing role of PML residue K394. Additionally, loss of USP22 upregulates interferon (IFN) and IFN-stimulated gene (ISG) expression in APL and induces PML-RARα stabilization and a potentiation of the cell-autonomous sensitivity towards all-<jats:italic>trans</jats:italic> retinoic acid (ATRA)-mediated differentiation. Our findings imply USP22-dependent surveillance of PML-RARα stability and IFN signaling as important regulator of APL pathogenesis, with implications for viral mimicry, differentiation and cell fate regulation in other leukemia subtypes.</jats:p>
  • Zugangsstatus: Freier Zugang